Skip to main content
Izotropic Corporation logo

Izotropic Corporation — Investor Relations & Filings

Ticker · IZO ISIN · CA46604F1099 LEI · 529900IZ5PIVM7X6S027 CSE Manufacturing
Open in API
Filings indexed 368 across all filing types
Latest filing 2021-11-22 Regulatory Filings
Country CA Canada
Listing CSE IZO

About Izotropic Corporation

https://izocorp.com/

Izotropic Corporation develops and commercializes diagnostic medical devices, specializing in advanced breast cancer detection technology. Its flagship product is IzoView, a dedicated Breast CT imaging platform. IzoView utilizes high-resolution, true 3D imaging without requiring breast compression, offering superior spatial resolution compared to traditional modalities. The system is purpose-built to improve diagnostic accuracy and patient comfort, particularly targeting the 50% of women with dense breast tissue where conventional screening tools are often inadequate. Izotropic is currently advancing IzoView through pivotal clinical studies toward product launch and commercialization.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2021-11-22 English
News release - English.pdf
Board/Management Information Classification · 95% confidence The document is a news release announcing the appointment of a new Head of Imaging Technology at Izotropic Corporation. It contains no financial data, no regulatory form references, no voting results, no financial performance details, and no mention of any report filings. The content is focused on management appointment and company news. Therefore, it fits best under Board/Management Information (MANG). The document length is 5744 characters, which is sufficient for a detailed announcement but does not contain financial or regulatory report content.
2021-11-05 English
News release - English.pdf
Regulatory Filings
2021-10-26 English
News release - English.pdf
Regulatory Filings
2021-10-13 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification by the Chief Financial Officer regarding the interim financial report and interim MD&A for the period ended July 31, 2021. It is a Form 52-109FV2 Certification of Interim Filings for a venture issuer. The content is primarily an officer certification letter confirming the accuracy and fair presentation of the interim filings, without containing the actual financial data or the interim report itself. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR). The document length is short (3013 characters), and it is clearly a certification rather than the report itself.
2021-09-29 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a FORM 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate, signed by the CEO certifying the review and fair presentation of the interim financial report and interim MD&A for the period ended July 31, 2021. It is a certification letter related to interim filings, not the interim report itself. The document is short (3005 characters) and primarily an officer certification. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS), not as the interim report (IR).
2021-09-29 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.